Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.35 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.34 |
| ▸ | PIM1 | P11309 | 5/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | XDH | P47989 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11909552 | 0.86 | LMNA (0.38) | MAP2K3PIM2PIM1PIM3DHODH | |
| SCHEMBL11907553 | 0.83 | FGFR2 (0.41) | MAP2K3PIM2PIM1PIM3DHODH | |
| SCHEMBL11907310 | 0.82 | FFAR4 (0.40) | FFAR4TRPV3KMOPIM2PIM1 | |
| SCHEMBL11907614 | 0.81 | PIM2 (0.35) | MAP2K3PIM2PIM1PIM3DHODH | |
| SCHEMBL11909253 | 0.81 | PPARD (0.37) | MCL1XDH | |
| SCHEMBL318644 | 0.79 | AR (0.37) | MAP2K3PIM2PIM1PIM3DHODH | |
| SCHEMBL11906508 | 0.77 | TRPV3 (0.54) | FFAR4TRPV3PIM2PIM1PIM3 | |
| SCHEMBL11907367 | 0.77 | DHFR (0.42) | — | |
| SCHEMBL11909713 | 0.76 | MAP2K3 (0.33) | MAP2K3PIM2PIM1PIM3DHODH | |
| SCHEMBL318994 | 0.75 | PIM2 (0.48) | MAP2K3PIM2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | FFAR4 3898/4885TRPV3 4536/4885MAP2K3 197/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | FFAR4 3898/4885TRPV3 4536/4885MAP2K3 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.